Clinical Trials Browser

Phase 3 × INDUSTRY × darolutamide × Clear all

NCT07611110 2026-05-28

VECTRA-01

Phase 3 Recruiting

Prostatic Neoplasms

NCT06120491 2026-05-27

EvoPAR-PR01

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05794906 2026-05-19

ARASTEP

Phase 3 Active not recruiting

Biochemically Recurrent Prostate Cancer

NCT04464226 2026-04-15

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Phase 3 Active not recruiting

Neoplasms

NCT04736199 2026-02-27

ARANOTE

Phase 3 Completed

669 enrolled 16 charts

Prostatic Neoplasms

NCT02799602 2025-12-04

ARASENS

Phase 3 Completed

1,306 enrolled 25 charts 2 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT02200614 2022-06-28

ARAMIS

Phase 3 Completed

1,509 enrolled 13 charts 1 FDA

Prostate Cancer Non-Metastatic